ImageneBio, Inc. (IMA) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
ImageneBio, Inc. stock (IMA) is currently trading at $5.56. ImageneBio, Inc. PS ratio (Price-to-Sales) is 79.55. Analyst consensus price target for IMA is $30.00. WallStSmart rates IMA as Sell.
- IMA PE ratio analysis and historical PE chart
- IMA PS ratio (Price-to-Sales) history and trend
- IMA intrinsic value — DCF, Graham Number, EPV models
- IMA stock price prediction 2025 2026 2027 2028 2029 2030
- IMA fair value vs current price
- IMA insider transactions and insider buying
- Is IMA undervalued or overvalued?
- ImageneBio, Inc. financial analysis — revenue, earnings, cash flow
- IMA Piotroski F-Score and Altman Z-Score
- IMA analyst price target and Smart Rating
ImageneBio, Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
ImageneBio, Inc. (IMA) · 5 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book. Concerns around market cap and operating margin. Significant fundamental concerns warrant caution or avoidance.
ImageneBio, Inc. (IMA) Key Strengths (1)
Trading below book value, meaning the market prices it less than net assets
Supporting Valuation Data
ImageneBio, Inc. (IMA) Areas to Watch (4)
Losing money on operations
Very expensive at 79.5x annual revenue
Micro-cap company with very limited liquidity and high volatility
Moderate institutional interest at 33.98%
Supporting Valuation Data
ImageneBio, Inc. (IMA) Detailed Analysis Report
Overall Assessment
This company scores 22/100 in our Smart Analysis, earning a F grade. Out of 5 metrics analyzed, 1 register as strengths (avg 10.0/10) while 4 fall into concern territory (avg 2.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book. Valuation metrics including Price/Book (0.48) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Operating Margin, Price/Sales, Market Cap. Some valuation metrics including Price/Sales (79.55) suggest expensive pricing. Profitability pressure is visible in Operating Margin at -501.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Operating Margin improves, as this is the primary drag on the overall score. Second, margin trajectory, with Operating Margin at -501.00% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Operating Margin and Price/Sales are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
IMA Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
IMA's Price-to-Sales ratio of 79.55x trades 410% above its historical average of 15.6x (89th percentile), historically expensive. The current valuation is 15% below its historical high of 93.93x set in Feb 2026, and 9259% above its historical low of 0.85x in Nov 2022. Over the past 12 months, the PS ratio has expanded from ~4.2x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for ImageneBio, Inc. (IMA) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
ImageneBio, Inc. operates as a stable business with moderate growth and solid fundamentals.
Key Findings
Debt-to-equity ratio of 0.08 indicates a conservative balance sheet with 103M in cash.
Spending 122% of revenue (5M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -7M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact ImageneBio, Inc..
Bottom Line
ImageneBio, Inc. offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About ImageneBio, Inc.(IMA)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. The company is headquartered in San Diego, California.